MTSL Issue 831

 Comments Off on MTSL Issue 831
Jul 172016
 
MTSL Issue 831

MTSL Issue 831 (dated 7/14/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ANTH #IONS #MDCO #ZIOP

Ziopharm (ZIOP) (7-15-16)

 Comments Off on Ziopharm (ZIOP) (7-15-16)
Jul 152016
 
Ziopharm (ZIOP) (7-15-16)

BIOINVEST BREAKING NEWS – Special Update – Ziopharm (ZIOP) – 3 Patients Die In The IL-12 Trial. ZIOP is down sharply this morning (7/15) on the report that three patients have died in their ongoing multicenter Phase I trial of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma (GBM) or grade III malignant glioma.

MTSL Issue 830

 Comments Off on MTSL Issue 830
Jul 042016
 
MTSL Issue 830

MTSL Issue 830 (dated 6/30/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ANTH #BMRN #FPRX #INCY #IONS #MDCO #ZIOP

MTSL Issue 829

 Comments Off on MTSL Issue 829
Jun 122016
 
MTSL Issue 829

MTSL Issue 829 (dated 6/09/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #FPRX #INCY #IONS #XON #NVAX #MDCO #SGMO #ZIOP

MTSL Issue 828

 Comments Off on MTSL Issue 828
May 292016
 
MTSL Issue 828

MTSL Issue 828 (dated 5/26/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #

Ziopharm (ZIOP) (5-16-16)

 Comments Off on Ziopharm (ZIOP) (5-16-16)
May 172016
 
Ziopharm (ZIOP) (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – ZIOP – Shows Rather Impressive Preclinical Data at ASGCT, Up Next Human Data at ASCO.
ZIOP was front and center at the 2016 Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington D.C. last week. The company presented exciting preclinical data for IL-12 in combo with a PD-1 that showed 100% survival. The non-viral Sleeping Beauty (SB) system was also on display. Read more…

MTSL Issue 827

 Comments Off on MTSL Issue 827
May 152016
 
MTSL Issue 827

MTSL Issue 827 (dated 5/12/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ANTH #FPRX #INCY #IONS #XON #MDCO #NKTR #NVAX #PCRX #ZIOP

MTSL Issue 826

 Comments Off on MTSL Issue 826
May 012016
 
MTSL Issue 826

MTSL Issue 826 (dated 4/28/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #BMRN #FPRX #INCY #IONS #NKTR #XON #ZIOP

MTSL Issue 817

 Comments Off on MTSL Issue 817
Dec 202015
 
MTSL Issue 817

Issue No. 817 (dated 12/17/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #ALKS #MDCO #NKTR #NVAX #OGXI #PCRX SGMO #ZIOP

MTSL Issue 816

 Comments Off on MTSL Issue 816
Dec 062015
 
MTSL Issue 816

Issue No. 816 (dated 12/3/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #BMRN #XON #MDCO #NKTR #NVAX #OGXI #SGMO #ZIOP

Wide World of Stocks (4-9-15)

 Comments Off on Wide World of Stocks (4-9-15)
Apr 092015
 
Wide World of Stocks (4-9-15)

Guest John McCamant, editor of the Medical Technology Stock Letter (MTSL), joins Wide World of Stocks host Damon Roberts to discuss a potential biotech bubble, merger mania, and opportunity with ZIOPHARM (NASDAQ: ZIOP)

Ziopharm Update (4-2-15)

 Comments Off on Ziopharm Update (4-2-15)
Apr 052015
 
Ziopharm Update (4-2-15)

ZIOP/XON Form Solid Partnerships With Merck KgaA & NCI CAR-T Superstar Rosenberg for Solid Tumors – ZIOP’s partner Intrexon (XON) has delivered two more exciting partnerships that ZIOP receives 50% of all assets and economics. The fact that the deals were both primarily announced by XON has caused a bit of confusion. For example, …